FDA Updates On Hyperinflation, Pancreatitis Risks Of Implantable Liquid-Filled Weight-Loss Balloons
A letter from the US agency clarifies the risks of over-inflation, acute pancreatitis and death in patients who have been treated with liquid-filled intragastric balloons.
You may also be interested in...
US FDA has approved updated labeling for Orbera Intragastric Balloon System and the ReShape Integrated Dual Balloon System in the wake of five more patient deaths.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.
Already cleared to monitor the viral load in HIV-positive individuals, the test has now been approved for initial diagnosis as well.